For dMMR/MSI-H colorectal cancer, there are approved anti-programmed cell death protein 1 (PD-1) antibodies called pembrolizumab and nivolumab for treating patients who have previously received chemotherapy. The gene discussed is PDCD1; the disease is colorectal cancer.